

# Recent Advances Against Blood Cancers

During the 12-month period—August 1, 2021, to July 31, 2022—covered by this report, the U.S. Food and Drug Administration approved several anticancer therapeutics to treat a wide range of hematological malignancies, including the following:

## MOLECULARLY TARGETED THERAPIES



### Asciminib (Scemblix)

- An inhibitor of the BCR/ABL oncogene—approved in October 2021 to treat **chronic myelogenous leukemia**.

### Zanubrutinib (Brukinsa)

- An inhibitor of an enzyme necessary for proliferation of B cells—approved in September 2021 to treat **Waldenström macroglobulinemia** and **marginal zone lymphoma**.

## IMMUNOTHERAPIES



### Brexucabtagene autoleucel (Tecartus)

- A CD19-directed chimeric antigen receptor T-cell therapeutic—approved in October 2021 to treat adult **acute lymphoblastic lymphoma**.

### Ciltacabtagene autoleucel (Carvykti)

- A BCMA- directed chimeric antigen receptor T-cell therapeutic—approved in February 2022 to treat **multiple myeloma**.

### Tisagenlecleucel (Kymriah)

- A CD19-directed chimeric antigen receptor T-cell therapeutic—approved in May 2022 to treat **follicular lymphoma**.

## COMBINATION THERAPIES



**A combination of rituximab (Rituxan)**—a molecularly targeted therapeutic—with **standard-of-care chemotherapy**, approved in December 2021 to treat **diffuse large B-cell lymphoma**, **Burkitt lymphoma**, **Burkitt-like lymphoma**, or **mature B-cell acute leukemia**.